Logos Capital
Logos Capital is an investment firm that provides financial solutions for the biotechnology sector.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Logos Capital Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
5,284,947Website Global Rank
1,736Website Monthly Traffic
Twitter Followers
Description
Logos Capital is an investment firm that provides financial solutions for the biotechnology sector.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2021 | Ikena Oncology | Series B | 0 |
| 10/2020 | LianBio | Series A | 0 |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
| 8/2021 | Vigil Neuroscience | Series B | 0 |
| 7/2021 | Nimbus Therapeutics | Private Equity Round | 105M |
| 7/2020 | Olema Oncology | Series B | 54M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 3/2023 | Unicycive Therapeutics | Post-IPO Equity | 0 |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 9/2019 | Passage Bio | Series B | 110M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 12/2020 | Cullinan Oncology | Series C | 131.2M |
| 2/2021 | Shoreline Biosciences | Series A | 0 |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 12/2021 | Freenome | Series D | 300M |
| 5/2021 | Gennao Bio | Series A | 40M |
| 12/2020 | SomaLogic | Series A | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 40M |
| 1/2021 | IconOVir Bio | Series A | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 12/2022 | Entact Bio | Series A | 81M |
| 9/2021 | Attralus | Series B | 116M |
| 1/2021 | Affinivax | Series C | 226M |
| 10/2022 | Immunovant | Post-IPO Equity | 75M |
| 10/2021 | Cedilla Therapeutics | Series B | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 4/2021 | GH Research | Series B | 125M |
| 3/2021 | Omega Therapeutics | Series C | 126M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 6/2021 | Element Biosciences | Series C | 276M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 4/2022 | Triana Biomedicines | Series A | 110M |
| 4/2021 | Janux Therapeutics | Series B | 0 |
| 9/2019 | Nkarta Therapeutics | Series B | 114M |
| 1/2022 | Septerna | Series A | 100M |
| 4/2022 | Grain | Series A | 16M |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 9/2021 | Obsidian Therapeutics | Series B | 0 |
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 4/2021 | Willow | Series C | 26.8M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
| 2/2021 | Centessa Pharmaceuticals | Series A | 250M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 3/2021 | Tyra Biosciences | Series B | 106M |
| 4/2021 | Boundless Bio | Series B | 105M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 3/2021 | DTx Pharma | Series B | 100M |
| 7/2020 | Annexon Biosciences | Series C | 100M |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 10/2021 | Quanta Therapeutics | Series C | 60M |
| 8/2020 | Dyne Therapeutics | Series B | 115M |
| 9/2020 | Flame Biosciences | Venture Round | 100M |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 10/2020 | Olema Oncology | Series C | 85M |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 11/2021 | Arbor Biotechnologies | Series B | 0 |
| 6/2022 | Elektrofi | Series B | 0 |
| 2/2022 | Parse Biosciences | Series B | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 9/2021 | RareCyte | Series G | 0 |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 6/2021 | Chronicle | Seed Round | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 2/2021 | Viracta Therapeutics | Post-IPO Equity | 65M |
| 6/2022 | Elektrofi | Series B | 0 |
| 4/2022 | Grain | Series A | 0 |
| 4/2022 | Triana Biomedicines | Series A | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Parse Biosciences | Series B | 0 |
| 1/2022 | Septerna | Series A | 0 |
| 1/2022 | Simcha Therapeutics | Series B | 0 |
| 1/2022 | Enliven Therapeutics | Series B | 0 |
| 12/2021 | Freenome | Series D | 0 |
| 12/2021 | Odyssey Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
